A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Xalatan Side Effects, and Drug Interactions - Latanoprost
Xalatan Side Effects, and Drug Interactions - Latanoprost
SIDE EFFECTS
Adverse Events Referred to in Other Sections of This Insert:
Eyelash changes (increased length, thickness, pigmentation, and
number of lashes); eyelid
skin darkening; intraocular
inflammation (iritis/uveitis);
iris pigmentation
changes; and macular edema, including cystoid
macular edema (see WARNINGS
and PRECAUTIONS).
Controlled Clinical Trials: The ocular
adverse events and ocular
signs and symptoms reported in 5-15% of the patients on latanoprost
in the 6 month, multi-center, double-masked, active-controlled trials
were blurred vision, burning and stinging, conjunctival hyperemia,
foreign body sensation, itching, increased pigmentation
of the iris, and punctate
epithelial keratopathy.
Local conjunctiva
hyperemia was observed;
however, less than 1% of the latanoprost treated patients required
discontinuation of therapy because of intolerance
to conjunctival hyperemia.
In addition to the
above listed ocular events/signs
and symptoms, the following were reported in 1-4% of the patients:
dry eye, excessive tearing, eye pain, lid
crusting, lid discomfort/pain,
lid edema, lid
erythema, and photophobia.
The following events were reported in less than 1% of the patients:
conjunctivitis, diplopia, and discharge
from the eye.
During clinical studies,
there were extremely rare reports of the following: retinal artery
embolus, retinal detachment,
and vitreous hemorrhage
from diabetic retinopathy.
The most common systemic
adverse events seen with latanoprost were upper respiratory tract
infection/cold/flu which occurred at a rate
of approximately 4%. Chest pain/angina pectoris, muscle/joint/back
pain, and rash/allergic skin reaction
each occurred at a rate
of 1-2%.
Clinical Practice: The following events have been
identified during postmarketing use of latanoprost in clinical
practice. Because they are reported voluntarily from a population
of unknown size, estimates of frequency cannot be made. The events,
which have been chosen for inclusion due to either their seriousness,
frequency of reporting, possible causal connection to latanoprost,
or a combination of these factors, include: eyelash changes (increased
length, thickness, pigmentation, and number of lashes); eyelid
skin darkening; intraocular
inflammation (iritis/uveitis);
macular edema, including cystoid
macular edema; toxic epidermal
necrolysis; asthma; exacerbation
of asthma; and dyspnea.
DRUG INTERACTIONS
In vitro studies have shown that precipitation
occurs when eye drops containing thimerosal
are mixed with latanoprost.
If such drugs are used they should be administered with an interval
of at least 5 minutes between applications.
top
